Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma

This study on biological samples of patients affected by neuroblastoma and Ewing sarcoma aims at validating the beta3-adrenoreceptor as prognostic biomarker.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neuroblastoma Ewing Sarcoma Neoplasms Neoplasms by Histologic Type Neoplasms, Bone Tissue Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Neuroectodermal Tumors, Primitive, Peripheral Osteosarcoma Sarcoma Sarcoma, Ewing

Age range

0 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Laboratorio traslazionale in oncoematologia

Florence, Italy, 50139

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

diagnosis of Ewing sarcoma or neuroblastoma

Exclusion criteria

sieropositivity

Treatment and study plan

beta3 expression

Diagnostic Test

the samples leftover from the standard diagnostic procedures will be analyzed for the expression of the beta3-adrenoreceptor

Primary outcomes

expression of beta3-adrenoreceptor

Time frame: from enrollment to the performance of the analysis that can take up to 6 weeks

Sponsors and collaborators

Lead sponsor

Meyer Children's Hospital IRCCS

Other

Registry information

Important dates

Study start: 2020
Primary completion: 2024
Study completion: 2024
First posted: Feb 28, 2025
Registry last updated: Feb 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed